Dr. Pinter-Brown is interested in optimizing treatment for patients diagnosed with lymphomas and is the principal investigator for clinical research protocols for patients with Hodgkin's disease, B-cell lymphomas, CD30+ Anaplastic large-cell lymphoma and T-cell lymphomas.
Selected Cancer-Related Publications:
Hu JC, Sadeghi P, Pinter-Brown LC, Yashar S, Chiu MW. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol. 2007; 56(2): 317-26.
Ghori F, Polder KD, Pinter-Brown LC, Hoff AO, Gagel RF, Sherman SI, Duvic M. Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides. J Clin Endocrinol Metab. 2006; 91(6): 2205-8.
Emmanouilides C, Colovos C, Pinter-Brown L, Hernandez L, Schiller G, Territo M, Rosen P. Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma. Clin Lymphoma. 2004; 5(1): 45-9.
Roberts AA, Amano M, Felten C, Galvan M, Sulur G, Pinter-Brown L, Dobbeling U, Burg G, Said J, Baum LG. Galectin-1-mediated apoptosis in mycosis fungoides: the roles of CD7 and cell surface glycosylation. Mod Pathol. 2003; 16(6): 543-51.